Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

fludarabine phosphate 42Cyclophosphamide 37Busulfan 30Cyclosporine 29Peripheral Blood Stem Cell Transplantation 28Cytarabine 27Mycophenolic Acid 24Antilymphocyte Serum 23Filgrastim 22Methotrexate 20Whole-Body Irradiation 17Radiotherapy 17Tacrolimus 16Methylprednisolone 13Cord Blood Stem Cell Transplantation 12Melphalan 11Etoposide 11Daunorubicin 10sargramostim 8fludarabine 8Idarubicin 8Granulocyte Colony-Stimulating Factor 8Thiotepa 6Cyclosporins 6tipifarnib 5merphos 5Topotecan 5Mitoxantrone 5Gemtuzumab 5Azacitidine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory, with Excess of Blasts × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡